Ann: Combined FOXFIRE Study Data Presented at ASCO Annual Meeting, page-2

"Dr David N. Cade, Chief Medical Officer of Sirtex Medical said "The presentation of the combined FOXFIRE analysis by Professor Sharma at ASCO now confirms that while SIR-Spheres plus systemic chemotherapy did not meet the primary endpoint of an overall survival advantage over chemotherapy alone, a statistically significant benefit was observed in objective response rates and liver-specific progression. "

"Also, the initial data presented from the SIRFLOX and FOXFIRE Global analyses, did confirm a statistically significant reduction in the risk of death for those patients who received SIR-Spheres plus chemotherapy with a right-sided primary colon cancer. "
This has to be very positive news for Sirtex!!!!